A Guide To Bioavailability Enhancement

Oral delivery remains the dominant route, yet bioavailability still complicates formulation for a significant share of new chemical entities. Attrition tied to poor drug-like properties has dropped sharply since the 1990s, but candidates increasingly fail beyond the rule of 5, and strict reliance on those guidelines may have cost sponsors real opportunities. This e-book weighs physical approaches, including solid dispersion and nanosuspension, against chemical ones such as lipid-based systems and cyclodextrin inclusion complexes. It also takes up a harder question: how study design, patient physiology, disease state, and genetics change what a bioavailability result actually tells you. A formulation case study reports solubility and bioavailability gains worth seeing in context.

Explore the e-book to compare the technologies side by side.